Australia markets closed

Alpine Immune Sciences, Inc. (ALPN)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
13.39+0.16 (+1.21%)
At close: 04:00PM EST
13.39 0.00 (0.00%)
After hours: 05:39PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 333.99M
Enterprise value 174.46M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)11.21
Price/book (mrq)2.72
Enterprise value/revenue 7.10
Enterprise value/EBITDA -4.38

Trading information

Stock price history

Beta (5Y monthly) 1.68
52-week change 319.51%
S&P500 52-week change 328.16%
52-week high 316.37
52-week low 37.87
50-day moving average 311.99
200-day moving average 310.80

Share statistics

Avg vol (3-month) 390.49k
Avg vol (10-day) 369.79k
Shares outstanding 529.22M
Implied shares outstanding 6N/A
Float 810.04M
% held by insiders 126.56%
% held by institutions 152.61%
Shares short (14 Nov 2021) 4407.19k
Short ratio (14 Nov 2021) 47.88
Short % of float (14 Nov 2021) 42.65%
Short % of shares outstanding (14 Nov 2021) 41.39%
Shares short (prior month 14 Oct 2021) 4417.62k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 324 July 2017
Ex-dividend date 4N/A
Last split factor 21:4
Last split date 324 July 2017

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sept 2021

Profitability

Profit margin -169.03%
Operating margin (ttm)-166.74%

Management effectiveness

Return on assets (ttm)-13.21%
Return on equity (ttm)-43.63%

Income statement

Revenue (ttm)24.56M
Revenue per share (ttm)1.02
Quarterly revenue growth (yoy)345.20%
Gross profit (ttm)-17.85M
EBITDA -40.3M
Net income avi to common (ttm)-41.51M
Diluted EPS (ttm)-1.72
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)180.63M
Total cash per share (mrq)6.18
Total debt (mrq)21.1M
Total debt/equity (mrq)17.18
Current ratio (mrq)2.87
Book value per share (mrq)4.20

Cash flow statement

Operating cash flow (ttm)-9.87M
Levered free cash flow (ttm)2.32M